Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
Overview
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
Source
Originally published at www.cnbc.com.
Related Articles
- Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
- Kalshi, Polymarket trading volumes on some products raises questions amid massive growth
- This is the big risk that stock investors should be watching as rising bond yields menace markets
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.